Other Corporate Information – ASCELIA

All All press releases Regulatory press releases Financial reports

2021-10-19 | Ascelia Pharma’s Food Effect Study with Orviglance successfully completed

Regulatory

2021-09-21 | Ascelia Pharma Signs Clinical Collaboration Agreement With Taiho Oncology, Inc. for the Development of Oncoral in Combination with LONSURF®

Regulatory

2021-08-18 | Covid-19 extends recruitment period of SPARKLE study

2021-08-13 | Abstract for Orviglance comparison study to gadolinium accepted at the world’s largest radiology conference RSNA

2021-08-10 | Ascelia Pharma receives conditional FDA acceptance for brand name Orviglance

Regulatory

2021-04-15 | Ascelia Pharma AB publishes prospectus regarding admission to trading of newly issued shares on Nasdaq Stockholm

Regulatory

2021-04-09 | Issue and repurchase of series C shares for share saving program

2021-03-02 | Ascelia Pharma opens US office in preparation for Mangoral launch

2021-01-12 | Ascelia Pharma presents clinical development plan for Oncoral as a novel chemotherapy

Regulatory

2020-12-15 | Ascelia Pharma gets US patent for second generation Mangoral

Regulatory

2020-12-02 | New study shows Mangoral’s lesion visualization as effective as gadolinium contrast agent

2020-11-03 | EMA confirms Mangoral eligible for the centralized regulatory procedure in the EU

Regulatory

2020-10-21 | Upgraded estimate of addressable market for Mangoral to $500-600 million annually

2020-09-18 | First commercial scale manufacturing of Mangoral

2020-05-26 | Vator Securities: Ascelia Pharma: A delay. Fundamentals for Mangoral remain unchanged.

Regulatory

2020-05-20 | Updated SPARKLE timelines due to Covid-19 impact

Regulatory

2020-05-06 | First participant enrolled in the clinical hepatic impairment study with Mangoral

2020-04-16 | Patent for Oncoral approved in Japan

2020-03-30 | Leading Ascelia Pharma through the Covid-19 period

2020-03-05 | Analysguiden/Carlsquare updates its view on Ascelia Pharma and raises target share price